This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Clinical Insider

New services firm Enosium Life Science plans to buy CROs

Posted by on 11 March 2024
Share this article

Private equity investor Otium Capital has set up Enosium Life Science, an advisory and scientific services provider intended to cater for pharmaceutical, biotech and medical technology firms.

Enosium Life Science will implement a targeted acquisition strategy, focusing on service providers in the contract research organization (CRO) space, regulatory affairs, market access, medical affairs, and marketing.

François Durvye, CEO of Paris, France-based Otium, framed the new firm as part of the organization’s efforts to foster innovation in the biopharmaceutical industry.

"Investing in Enosium Life Science demonstrates our commitment to supporting innovation and excellence in this key field,” he said, adding the firm will aim to “address the major challenges in medical innovations and improving patients’ health and quality of life."

The new group – details of which were unveiled this month – was set up in collaboration with biopharma industry veteran Antoine Amer, who will serve as CEO.

"Our vision is to combine the best expertise across Europe, providing a unique and comprehensive range of scientific services to address growing complexities in the European healthcare ecosystem, which will enable faster and broader access to medical innovations for patients" Amer said.

Otium Capital – which has €1.5 billion ($1.6 billion) in assets under management - invests across various domains. In the healthcare space this includes Quantum Genomics, a biopharmaceutical company that develops therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

The organization also has a holding in the growth equity fund Techlife Capital, which in turn has investments in several biopharmaceutical service providers including Toulouse, France-based CDMO Flash Therapeutics.

Through Techlife, Otium also has an interested in Paris-headquartered drug repurposing specialist Mitem Pharma, which identifies markets that are poorly addressed by existing drugs and secures their supply, revives them, improves them, or develops new medicines.


Share this article

Sign up for Clinical Insider email updates